Dupilumab, a fully human monoclonal antibody targeting IL-4 and IL-13 by blocking IL-4Rα signaling [17], has been shown to improve the clinical disease activity, immune abnormalities, and epidermal barrier function, thereby highlighting IL-4Rα signaling as a key driver of the AD phenotype [18,19,20]. Here, IL4R is linked to Alzheimer disease.